Bispecific Antibody Development for Autoimmune Diseases

Although bispecific antibodies for autoimmune diseases remain in the early stages of development, significant advances have been made in the treatment of rheumatoid arthritis (RA), ulcerative colitis (UC), systemic lupus erythematosus (SLE), asthma, psoriasis, and other autoimmune diseases. These existing and developing agents may offer new options for personalized therapy. As a global leading biopharmaceutical company, Creative Biolabs has advanced facilities, the latest technologies, and experienced experts. We are confident in offering high-quality bispecific antibody development services for global researchers.

Introduction of Bispecific Antibody

The concept of bispecific antibodies was first suggested nearly 50 years ago, and it is finally coming of age for the generation of therapeutic agents. Historically, a major obstacle to developing bispecific antibodies as therapeutic agents is the difficulty in designing these complex molecules with favorable drug-like properties and producing them in sufficient quantity and quality to support drug development. Bispecific antibodies as potential therapeutic agents have undergone a renaissance in recent years, facilitated by the advent of numerous alternative formats and improved methods for their more efficient generation, optimization, and production. Moreover, a greater understanding of disease pathogenesis is leading to better choices of target antigen and antibody pairs.

Bispecific Antibody Application in Autoimmune Disease

Antibody drugs have been widely used to treat millions of patients with autoimmune and inflammatory diseases, including RA, SLE, psoriasis, UC, Crohn's disease, and multiple sclerosis. Autoimmune disease control with antibody therapy is highly successful. However, successful treatment with therapeutic antibodies remains challenging, at least partly because inflammatory diseases are complex and heterogeneous. Rates of clinical remission are often relatively low. For example, approximately 20-30% of patients with RA are refractory to anti-TNF therapy or show partial responses. The crosstalk of pro-inflammatory mediators may limit the efficacy of antibody treatment.

Until now, diverse antibody engineering approaches have been developed to improve the clinical efficacy of antibody drugs such as antibody structure optimization, antigen affinity enhancement, or drug conjugation, and so on. One such important strategy is the generation of bispecific antibodies that selectively disrupt multiple biological pathways by blocking two interrelated or unrelated antigens, including soluble molecules or cell surface receptors. The use of bispecific antibodies is likely a future exploratory direction for the management of autoimmune diseases. Researchers are now focusing on the status and recent clinical progress of bispecific antibodies in autoimmune and inflammatory conditions.

Custom Services of Bispecific Antibody Development for Autoimmune Diseases

Focusing on drug development for autoimmune disease for years, Creative Biolabs has accumulated extensive experience from hundreds of successful previous projects. Our solid experimental foundation, professional scientific staff, and rich experience are the guarantee that assures the quality of our services.

• Professional: A team of experts with Ph.D. level degrees
• Reliable: Hundreds of customer-satisfied precedents
• Worry-free: One-stop services with high efficiency

With a comprehensive drug development platform and extensive experience, Creative Biolabs is eager to promote the discovery of novel drugs for autoimmune diseases through our reliable bispecific antibody development services. If you are interested in our services or you have any other questions, please feel free to contact us for more information.

For Research Use Only | Not For Clinical Use